MRC1 and neoplasm: Following a study demonstrating that MMR deficient tumours with increased MSI have a higher response rate to pembrolizumab than MMR proficient tumours [13], pembrolizumab was approved by the FDA for the treatment of advanced solid tumours with the MSI-high or DNA MMR deficiency biomarker in 2017.